in research institute for nuclear medicine (tehran university of medical sciences) 50 patients with follicular thyroid carcinoma were evaluted retrospectively. the purpose of the study was assesment of the response of iodine-131 therapy. the best result were achieved when the patient treated with iodine-131 for the first time, in the 4th decade of life, with total thyroidectomy and no metastasi...

Iodine-131 ((131)I) administered to patients for imaging or treatment, concentrates in the gastrointestinal tract, including the salivary glands, stomach and bowel. In Nuclear Medicine practice this biological property of iodine causes side effects when the therapeutic dose of (131)I is large. This occurs during the treatment of patients with differentiated thyroid carcinoma (DTC). During this ...

Iodine-131 is successfully used in the treatment of hyperthyroidism and differentiated thyroid cancer. Thyroid is the critical organ for iodine. Iodine is taken up by the thyroid follicular cells. Radioactive isotope iodine-131 simultaneously emits two types of radiation: radiation beta minus (β-) used for the treatment and gamma (γ) used for diagnosis. Due to the penetration of beta particles ...

introduction: recombinant human thyroid-stimulating hormone(rhtsh) increases radioactive iodine uptake(raiu) in selected populations, while lithium is used as an adjunct to radioactive iodine (rai) therapy in graves’ disease with low raiu. in this report, both drugs used in combination, overcame low iodine-131 uptake in a graves’ patient. clinical case: a 39-year old female with graves’ disease...